Abstract: An efficient fusion expression system with a small fusion partner, His6-tagged N-terminal fragment of staphylococcal nuclease R, has been constructed and tested with two genes. The results show that the system is not only suitable for overexpression of small proteins and peptides but simplifies purification of target proteins and peptides. The study also provides a practical method for preparation of isotope-labeled protein sample for NMR analysis.
protein of 125 residues [3, 4] and a myotoxin α (MYO) peptide of 42 residues [5] were N-terminally fused with the fusion partner. There is a thrombin (LVPR↓GS) or a hydroxylamine (N↓G) cleavage site between the fusion partner and target protein for removing the fusion partner. It is worth noting that PDCD5 protein was directly expressed with very low yield in M9 medium, and myotoxin α was hardly expressed even if it was fused with GST fusion partner in LB medium in our previous experiments (unpublished observation).
The results show that this fusion expression system not only allows target proteins to be highly expressed but also simplifies purification of the isotope labeled target proteins for NMR analysis.
MATERIALS AND METHODS

Bacterial strains and plasmids
E. coli DH5α and BL21(DE3) were used as the cloning and expression host cells, respectively.
pBV-3 [6] , pMT4TFAR19 [4] and pUC-MYO containing the coding sequence for myotoxin α that were used as PCR templates for amplifying fusion partner HR52, PDCD5 and myotoxin α gene respectively. pUC18 was used as the vector for cloning the fusion protein genes and DNA sequencing. pET-3d was kindly provided by Dr. Studier as the vector for expression of fusion proteins.
DNA MANIPULATIONS
Restriction endonucleases and T4 DNA ligase were used as recommended by the manufacturer (Promega). Plasmid isolation and transformation of CaCl2-treated E. coli cells were carried out by the procedure described by Sambrook et al. [7] . The fusion partner HR52 was amplified from pBV-3 using two primers: primer1 (18mer, 5'-ATGAATTCCATGGGCCAC-3' containing EcoRI and NcoI sites) and primer 2 (26mer, 5'-TAGGTACCCTCTACACGTTTTTTAGG-3' Kpn I tail with a TA clamp at 5' end) were used as the forward and reverse primers, respectively. The amplified HR52 sequence was digested with EcoRI and Kpn I enzymes, and then ligated into EcoRI/Kpn I digested pUC18 and this plasmid was designated pUC18-HR52.
Primer 3 [42mer, 5'-GGGGTACC CTGGTTCCGCGTGGTTCC GCGGACGAGGAGCTTG-3', Kpn I tail with a GG clamp at the 5' end, followed by a thrombin cleavage site (LVPR↓GS) coding sequence, (in box)] and primer 4 (32mer, 5'-AAGGATCCATTAATAATCGTCATCTTCATCAG-3', BamHI tail with a AA clamp at 5' end) were used as the forward and reverse primers, respectively, to amplify the PDCD5 coding sequence using pMT4TFAR19 as the template. The PCR product was digested with Kpn I and BamHI and the PDCD5 coding sequence was ligated with T4 DNA ligase into Kpn I and BamHI sites of pUC18-HR52 to yield PDCD5 coding sequence fused to HR52 gene in frame, and this was designated pUC18-HR52-PDCD5. After transformation of the plasmid into E .coli DH5α, the clone was validated by DNA sequencing. The target gene encoding myotoxin α was also amplified from pUC-MYO by using the same procedure as described above except that a hydroxylamine cleavage site N↓G was introduced between the fusion partner and myotoxin α instead of the thrombin cleavage site. Finally, the expression plasmid pET-HR52-PDCD5 or pET-HR52-MYO was obtained by insertion of the HR52-PDCD5 or HR52-MYO fragment into the NcoI and BamHI sites of pET-3d vector.
Expression, labeling and purification of HR52-PDCD5
A fresh BL21(DE3) clone harboring pET-HR52-PDCD5 was inoculated in 200 ml of LB medium containing 100 µg/ml ampicillin and cultured at 37°C until the optical density (A600) reached 0.8. The whole culture was then transferred to 1 L of the same medium and cultured at 37°C until optimal density (A600) reached 0.6. After centrifugation, the cell pellet was inoculated in 1 L of pre-warmed M9 medium except substituting the 15 NH4Cl for NH4Cl and/or 13 C glucose for glucose and cultured at 37°C for 0.5 h, and then IPTG was added to a final concentration of 0.4 mM. After induction at 37°C for 4 h, the cell pellet was collected by centrifugation at 6000 g for 20 min at 4°C, and then resuspended in 50 ml of buffer A (50 mM Tris-HCl, pH 8.0, 500 mM NaCl), followed by ultrasonication on ice for 1 min ×5 to break the cells. The supernatant (45 ml) was recovered after the lysed bacteria were centrifuged at 37,000 g at 4°C for 30 min and directly applied onto a 5×1 cm 2 of chelating Sepharose Fast Flow column at a flow rate 1.0 ml/min, which was charged with Ni 2+ prepared according to the producer's protocol (Amersham Biosciences) and equilibrated with the same buffer. The column was washed first by a 50 ml of buffer A followed by a 50 ml of buffer B (50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 25 mM Imidazole). Finally the column was eluted with buffer C (50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 250 mM Imidazole), and monitored by absorbance at 280
nm. The major peak of protein was collected and this was followed by dialysis against distilled water at 4°C.
The protein was then lyophilized and stored at -20°C.
The protein samples from each step as described above were analyzed by using 10% SDS-PAGE according to the Blackshear procedure [8] , which is a minor modification of the SDS-Tris-glycine system of Laemmli [9] . Proteins were visualized by staining with Coomassie brilliant blue R250.
Thrombin Cleavage of HR52-PDCD5 and Purification of PDCD5
To cleave out the fusion protein HR52, 40 mg of HR52-PDCD5 was dissolved in 20 ml of buffer D 
Expression and purification of myotoxin α
For expression of HR52-myotoxin α, bacterial culture and induction were carried out in the routine way in LB medium. Soluble HR52-myotoxin α fraction was also purified by using Ni
2+
-chelating affinity chromatography as described above. 38 mg of HR52-myotoxin α was cleaved with hydroxylamine by the method described by Mokes et al [10] . Myotoxin α was purified through second run of Ni 
RESULTS AND DISCUSSION
Construction of fusion expression vector for expression of PDCD5 and myotoxin α
As described in Materials and Methods, to construct the fusion expression vector, the fusion partner coding sequence, HR52, was inserted into pUC18 with EcoRI and Kpn I cut sites to create pUC18-HR52 first. The target gene, PDCD5 or myotoxin α, was then inserted into the pUC18-HR52 with Kpn I and BamHI cut sites to yield pUC18-HR52-PDCD5 or pUC18-HR52-MYO. Finally, the DNA fragment encoding HR52-PDCD5 or HR52-MYO cut from the above plasmids with NcoI and BamHI enzymes were inserted into pET-3d with the same cut sites to obtain pET-HR52-PDCD5 or pET-HR52-MYO for fusion expression of the target genes. As shown in Figure 1 , the fused target gene (HR52-PDCD5 or HR52-MYO) is under the transcriptional control of T7 promoter, and the strong T7 transcription termination is placed downstream of the genes. The HR52-PDCD5 and HR52-MYO genes are placed in the correct reading frame with the initiation codon (ATG) supplied by pET-3d vector. The initiation codon of the fusion protein genes is within 7 bp from the SD sequence. The thrombin or hydroxylamine cleavage site, which will be used to prepare PDCD5 and myotoxin α by using thrombin and hydroxylamine cleavage of the fusion proteins, respectively, is placed between the fusion partner and target protein. 
Analysis of expression of the HR52-PDCD5 and HR52-myotoxin α in E. coli BL21 (DE3)
Expression of the fusion genes in E. coli was analyzed by SDS-PAGE. Fig.2A shows the 10% SDS-PAGE pattern of the cell lysate from E. coli cells harboring pET-HR52-PDCD5 before and after induction with IPTG. Compared with the uninduced cells (Fig.2A, lane 2) , an intensely staining protein band can be observed in the induced total cell lysate ( Figure 2A, lane 3) , which constitutes more than 25% of the total cellular proteins of the bacterial cell as analyzed by scanning the protein density of the gel. Note that most of HR52-PDCD5 fusion protein is in the supernatant of the cell lysate (Figure 2A, lane 5) , indicating that most of the desired recombinant protein is expressed in soluble form. The expression pattern of HR52-myotoxin α was also analyzed by using SDS-PAGE. As shown in Figure 3A , HR52-myotoxin α was highly expressed in E. coli cells, and constitutes more than 40% of the total cellular proteins of the bacterial cell ( Figure 3A, lane 3) . About 40% of the desired fusion protein is expressed in soluble form ( Figure 3A , lane 5). It is worth noting that myotoxin α gene could not be expressed when it was fused with GST using pGEX expression vector (unpublished observation). The results indicate that the fusion expression system is suitable for fusion expression of small peptides and proteins.
Simplifying purification of target proteins
Since the fusion partner in the expression vector is a His6-tagged N-terminal fragment of staphylococcal nuclease R (HR52), fusion proteins can be first purified by using a routine metal-chelating affinity chromatography procedure. As shown in Figure 2B -chelating affinity chromatography at the denaturing conditions. The main peak was obtained by using elution buffer (0.1 M phosphate buffer, pH 4.5, 6 M GuHCl). 100 mg of HR52-myotoxin α can be obtained. However, hydroxylamine cleavage in denaturing solution is less efficient and the recovery rate of myotoxin α is low as shown in Figure 3B .
In summary, this study not only provides an efficient fusion expression system for small protein and peptide expression in E. coli cells but also provides a practical method for preparation of isotope labeled protein samples for NMR analysis. Any gene can be inserted into the vector with Kpn I and BamHI sites after amplification with appropriate PCR primers. Target proteins or peptides can be obtained after cleavage of fusion proteins with thrombin or hydroxylamine, which are purified by using one-step metal chelating affinity chromatography. In addition, to suppress the basal expression of the fusion protein, the NcoI-BamHI cassette (Figure 1 ) can be also inserted into other pET vector, such as pET-15b and pET-28a
[12] using the same restriction enzyme sites. Thus the basal expression of the fusion genes is minimized by the binding of the lac repressor encoded by the lacI gene, to the lac operator immediately downstream of the T7 promoter.
